专业的生物医药CDMO服务供应商
烟台迈百瑞国际生物医药股份有限公司(MabPlex International),生物制药企业优质合作伙伴。凭借创新的技术、丰富的经验、专业的团队,帮助客户完成生物药物从研发到商业化生产,加快新药上市,助力中国生物医药产业发展,捍卫人类健康。先后建立并成功运行迈百瑞美国、迈百瑞上海,持续拓展国内、国际市场。是山东省抗体药物研发和产业化公共服务平台承担单位,国家高新技术企业。
烟台迈百瑞国际生物医药股份有限公司(MabPlex International),生物制药企业优质合作伙伴。凭借创新的技术、丰富的经验、专业的团队,帮助客户完成生物药物从研发到商业化生产,加快新药上市,助力中国生物医药产业发展,捍卫人类健康。先后建立并成功运行迈百瑞美国、迈百瑞上海,持续拓展国内、国际市场。是山东省抗体药物研发和产业化公共服务平台承担单位,国家高新技术企业。
迈百瑞拥有CHO细胞大规模培养与ADC技术平台、丰富的CMC管理与注册申报经验,可为客户提供单抗、双抗、融合蛋白、抗体偶联药物、重组疫苗、重组蛋白等生物药提供专业化、定制化、一体化的CDMO服务,可覆盖从早期研发、细胞株开发、生产工艺开发、分析方法开发、质量研究、临床样品生产、国内外IND/BLA申报到大规模商业化生产的全链条环节。迈百瑞在生物药CDMO领域(尤其是抗体药物ADC方面)具有较强竞争优势,是目前全球少数具备提供抗体偶联药物全链条CDMO服务的公司之一。
首席执行官   李新芳博士
北京大学分子生物学和生物化学博士,美国哈佛医学院博士后。拥有丰富的工艺开发、CMC和CMO管理经验,主持参与了十几个单抗和ADC的CMC和临床申报、数个抗体与ADC项目的工艺表征及商业化的生产验证工作。“Biophorum Operations Group”病毒去除验证分组成员,病毒去除研究专家,拥有多项工艺开发发明专利。
科学顾问    黄长江博士
美国衣阿华州立大学博士,分别在南加州大学生殖生理学专业、加州大学洛杉矶分校神经内分泌专业完成博士后研究,是率先开展ADC新药研究并取得成果的学者之一。从事生物医学研发30多年,先后在美国《糖尿病》《生物化学》《神经科学》等学术期刊中发表上百篇论文,拥有发明专利数十项。
首席战略官 陈巍博士
日本名古屋大学生化反应工程生物工程博士,于耶鲁大学、英属哥伦比亚大学从事分子病毒学方面的博士后研究。拥有30多年国际生物医药公司大规模产业化平台建立、CMC管理、新药申报等多方面经验,参与多家生物医药公司的创立及上市。
烟台迈百瑞国际生物医药有限公司成立
烟台生产研发中心正式启用
迈百瑞美国公司(MabPlex USA, Inc)成立
建成“山东省病原微生物实验室”
通过环境管理体系
及职业健康安全管理体系认证
获得生物工程产品
《药品生产许可证》
美国圣地亚哥研发中心成立
迈百瑞生物医药(上海)有限公司成立
通过知识产权管理体系认证
山东省抗体药物研发和产业化公共服务平台揭幕
迈百瑞M2 GMP设施运行启动
董事长房健民博士入选科技部创新人才推进计划
完成首次A轮融资,融资金额3.9亿元
迈百瑞M2 GMP设施投入商业化运营
迈百瑞上海全面运行启动
迈百瑞入选国家高新技术企业
完成首次B轮融资,融资金额5亿元
荣获“亚太地区抗体及 ADC
制造工艺卓越奖”
入选山东省瞪羚企业
入选国家专精特新
“小巨人”企业
荣膺 Life Sciences Review 2021“TOP 10 CROs”榜单
迈百瑞国际生物医药创新中心暨运营总部奠基
中国(山东)自由贸易试验区烟台片区
烟台开发区北京中路60号
中国(山东)自由贸易试验区烟台片区 烟台开发区北京中路60号
投资者关系: (+86)535-3573687 IR@mabplex.com
商务合作:(+86)535-3573215
BD@mabplex.com
烟台迈百瑞国际生物医药股份有限公司对网站的内容独立负责
互联网药品信息服务证书:(鲁)-非经营性-2014-0097 鲁ICP备14008329号-1
Dr. Chen has 30 years of experience in the establishment of large-scale industrialization platforms, quality management, and new drug declaration for international biopharmaceutical companies including Bristol Myers Squibb, Johnson & Johnson, Pfizer, and Merck. He has a Ph.D. in Bioreactor Engineering from Nagoya University, Japan. He is also a Postdoctoral Fellow at UCLA, University of British Columbia Medical School, and Yale University Medical School.
Previously responsible for new drug development and industrialization of various new biological drug development, Dr. Chen has experience in the establishment and listing of multiple biomedical companies, participated in the creation of the internationally renowned CDMO company BioReliance, and is responsible for operation management. Dr. Chen is a member of the International Society of Industrial Microbiology, the founder of the Microbiome Society and the International Biopharmaceutical Engineering Alliance.
Dr. Fang has a Ph.D. from Dalhousie University, Canada, and post-doctoral fellow at Harvard Medical School, working in the United States for many years on biopharmaceutical research and development. He is a member of the Taishan Scholars program in Shandong Province, a member of the National Expert Group on Major New Drug Creation, professor and doctoral tutor of Tongji University and the Dean of Suzhou Research Institute of Tongji University. Dr. Fang’s research results have been published in several journals including Natural Biotechnology, Journal of the Americal Academy of Sciences, and Oncology Research, with more than 30 invention patents, and many projects have achieved transformation. He is the inventor and designer of Conbercept. He is a member of the China Pharmaceutical Association, the Deputy Chairman of the Malonal Antibody Professional Committee of the China Pharmaceutical Innovation Promotion Association. He has won the second prize of the National Science and Technology Progress Award, Chinese Overseas Chinese Contribution Award, and China Industry-University-Research Cooperation Innovation Award.
Dr. He has a Ph.D. and is a postdoctoral fellow in pharmacology from Einstein College of Medicine, USA and MBA from City University of New York. He has been engaged in customer development and business development for a long time in the United States, successfully promoted the business growth of many internationally renowned CDMO companies, and has extensive experience in marketing and product listing. Dr. He has published more than 20 scientific articles.
Dr. Huang has a Ph.D. from Iowa State University, completed postdoctoral research in reproductive physiology at the University of Southern California and neuroendocrinology at the University of California, Los Angeles. He is one the first scholars to carry out research on ADC new drugs and has achieved results, and is a special expert of Taishan Scholar program in Shandong Province. He has been engaged in biomedical research and development for more than 30 years and has published hundreds of papers in academic journals such as Diabetes, Biochemistry, and Neuroscience. Member of the American Society of Cell Biology, member of the International Neurochemical Society, member of the American Diabetes Association, and member of the American Association for the Advancement of Science.
Dr. Li has a Ph.D. in Molecular Biology and Biochemistry from Peking University, postdoctoral researcher at Harvard Medical School, a member of the Biophorum Operations Group, a virus removal validation group, and an expert in virus removal research for antibody downstream processes. She has extensive experience in CMC and CMO management and has participated in the process characterization and commercial production verification of several mAb and ADC projects. She has worked for more than ten years in the world’s first company to engage in the development of new ADC drugs. She has served as the Chief Scientist, the head of the process development department, and the leader of the drug-making evaluation team for new drugs. Having both applied for IND in the US and Europe, of which seven are self-developed new drugs and six are developed in cooperation with internationally renowned pharmaceutical companies for the development of CRO / CMO projects. Among them, T-DM1, the first in the world to treat HER2-positive breast cancer, was approved by the FDA in 2013. Initiated a new one-step coupling production process, led the team to overcome the technical problems of ADC coupled polymers and unconjugated naked antibodies with high content and improved the coupling efficiency. Participated in publishing several virus removal verification papers.
Dr. Yongjian has a Ph.D. in immunology from the University of Toronto, Canada, a postdoctoral fellow in neurobiology at Standford University. He has nearly 20 years of working experience in the biopharmaceutical industry and has been engaged in R&D and management of well-known pharmaceutical companies such as Bayer and Genentech. He has extensive experience in the research and development of protein therapy (biological agents, including monoclonal antibodies, ADCs, and biosimilars), and is particularly good at the technology and management of CMC development such as protein engineering, cell line development, biological detection, and protein chemistry.
Dr. Zhigang has an MBA from the Kelley School of Business, Indiana University, and an MS in Chemistry from the University of Louisville. He has accumulated more than 20 years of pharmaceutical production quality management experience in well-known pharmaceutical companies such as Abbott, Eli Lilly, Amgen, Wuming Bio. Proficient in quality compliance operations under the requirements of the US FDA, Chinese NMPA and ICH laws and regulations, especially with a deep understanding of the phase adaptability of GMP can be effectively used. Presided over the establishment and improvement of the company’s quality system multiple times. Facility verification, including the release of many clinical and marketed products.
Dr. Babiuk is a fellow of the Royal Society of Canada and Fellow of the European Academy of Sciences. He holds 42 patents, part-time positions in the editorial boards of more than 40 international scientific organizations and science and technology journals, invited reviewer of 16 science and technology magazines and members of the board of directors of more than 20 biotechnology companies. He has won 57 awards, including the Queen Elizabeth II Diamond Commemorative Media, The Canadian Arts Council Award, the 2016 China GCHERA World Agriculture Award, and more than 20 “1000 International Scientific Leaders” and “World Health Science Leaders” awards.